Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials

Journal of Acquired Immune Deficiency Syndromes

Volumn 60, Issue 1, 2012, Pages 33-42

  Cohen, Calvin J ^a   Molina, Jean Michel ^b   Cahn, Pedro ^c   Clotet, Bonaventura ^d   Fourie, Jan ^e   Grinsztejn, Beatriz ^f   Wu, Hao ^g   Johnson, Margaret A ^h   Saag, Michael ⁱ   Supparatpinyo, Khuanchai ^j   Crauwels, Herta ^k   Lefebvre, Eric ^m   Rimsky, Laurence T ^k   Vanveggel, Simon ^k   Williams, Peter ^k   Boven, Katia ^l  

^a Boston Community Research Initiative of New England   (United States)

^b SAINT LOUIS HOSPITAL   (France)

^c HOSPITAL JUAN A FERNÁNDEZ   (Argentina)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e Dr J Fourie Medical Centre   (South Africa)

^f Funda??o Oswaldo Cruz   (Brazil)

^g CAPITAL MEDICAL UNIVERSITY   (China)

^h ROYAL FREE HOSPITAL   (United Kingdom)

ⁱ University of Alabama at Birmingham   (United States)

^j CHIANG MAI UNIVERSITY   (Thailand)

^k JANSSEN RESEARCH FOUNDATION   (Belgium)

^l JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^m NONE

more..

Author keywords

Efavirenz or EFV; HIV 1; Rilpivirine or RPV; Treatment naive

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; RILPIVIRINE;

ABNORMAL DREAMING; ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NIGHTMARE; PATIENT COMPLIANCE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RANDOMIZATION; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; NITRILES; PYRIMIDINES; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84862777419     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31824d006e     Document Type: Article

References (36)

1. Prescribing information for Edurant® (rilpivirine) tablets. Janssen-Cilag, May 2011. Available at: http://www.accessdata.fda.gov/drugsatfda- docs/label/2011/202022s000lbl.pdf. Accessed May 28, 2011.
2. Edurant® (rilpivirine) tablets summary of product characteristics. Janssen- Cilag, November 2011. Available at: http://www.medicines.org.uk/EMC/ medicine/25490/SPC/Edurant+25+mg/. Accessed December 2, 2011.
3. Prescribing information for Complera® (emtricitabine/rilpivirine/ tenofovir disoproxil fumarate) tablets. Gilead Sciences, August 2011. Available at: http://www.gilead.com/pdf/complera-pi.pdf.Accessed August 11, 2011.
4. Eviplera® (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) tablets summary of product characteristics. Gilead Sciences, November 2011. Available at: http://www.medicines.org.uk/EMC/medicine/25518/SPC/ Eviplera+200+mg+25+mg+245+mg+film+coated+tablets/.Accessed December 9, 2011.
5. Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378:238-246.
6. Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011; 378:229-237.
7. Rimsky L, Vingerhoets J, Van Eygen V, et al. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defic Syndr. 2012;59:39-46.
8. Vingerhoets J, Rimsky L, Van Eygen V, et al. Screening and baseline mutations in the TMC278 phase III trials ECHO and THRIVE: prevalence and impact on virological response [abstract 41]. Antivir Ther. 2011;16(suppl 1):A51.
9. FDA Guidance for Industry. Antiretroviral drugs using plasma HIV RNA measurements-clinical considerations for accelerated and traditional approval, prepared by the Division of Antiviral Drug Products: Office of Drug Evaluation IV in the Centre for Drug Evaluation and Research (CDER), Appendix B, October 2002. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/UCM070968.pdf. Accessed March 16, 2011.
10. Division of Acquired Immune Deficiency Syndrome (DAIDS) table for grading the severity of adult and pediatric adverse events. Version 1. December 28, 2004. Available at: http://rsc.tech-res.com/safetyandpharmacovigilance.Accessed March 8, 2012.
11. van Velsen F, Sternberg J, Lachau-Durand S, et al. Study of the endocrine effects of TMC278, a novel HIV-NNRTI, in juvenile female cynomolgus monkeys [abstract 622]. Presented at: 50th Annual Meeting of the Society of Toxicology; March 6-10, 2011; Washington DC.
12. Pozniak AL, Morales-Ramirez J, Katabira E, et al. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS. 2010;24:55-65.
13. Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med. 2009;17:138-145.
14. DeJesus E, McCarty D, Farthing CF, et al. Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial. Clin Infect Dis. 2004;39:411-418. (Pubitemid 39050491)
15. DeJesus E, Herrera G, Teofilo E, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral- naive HIV-infected adults. Clin Infect Dis. 2004;39:1038-1046. (Pubitemid 39313463)
16. Moyle GJ, DeJesus E, Cahn P, et al. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study. J Acquir Immune Defic Syndr. 2005;38:417-425. (Pubitemid 40381551)
17. Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naïve patients: virologic, immunologic, and morphologic changes-a 96-week analysis. J Acquir Immune Defic Syndr. 2006;43:535-540. (Pubitemid 44885619)
18. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double- blind randomised controlled trial. Lancet. 2009;374:796-806.
19. Smith KY, Kumar PN, Patel P, et al. Differences in virologic response among African-Americans and females regardless of therapy in the HEAT study [abstract MOPEB033]. Presented at: 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; July 19-22, 2009; Cape Town, South Africa.
20. Kumar P, Currier J, Squires K, et al. Predictors of response in GRACE (Gender, Race And Clinical Experience) [poster 335]. Presented at: 47th Annual Meeting of the Infectious Diseases Society of America; October 29-November 1, 2009; Philadelphia, PA.
21. Fourie J, Flamm J, Rodriguez-French A, et al. Effect of baseline characteristics on the efficacy and safety of once-daily darunavir/ritonavir in HIV-1-infected, treatment-navie ARTEMIS patients at week 96. HIV Clin Trials. 2011;12:313-322.
22. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med. 2007;146:564-573. (Pubitemid 351650537)
23. Knobel H, Guelar A, Carmona A, et al. Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors. AIDS Patient Care STDS. 2001;15:193-199. (Pubitemid 32374225)
24. Goldman JD, Cantrell RA, Mulenga LB, et al. Simple adherence assessments to predict virologic failure among HIV-infected adults with discordant immunologic and clinical responses to antiretroviral therapy. AIDS Res Hum Retroviruses. 2008;24:1031-1035.
25. Back DJ, Khoo SH, Gibbons SE, et al. Therapeutic drug monitoring of antiretrovirals in human immunodeficiency virus infection. Ther Drug Monit. 2000;22:122-126. (Pubitemid 30083112)
26. Mocroft A, Phillips AN, Friis-Møller N, et al. Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study. Antivir Ther. 2002;7:21-30. (Pubitemid 36285548)
27. Egger M, May M, Chêne G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-129. (Pubitemid 34786200)
28. Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of oncedaily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS. 2008;22:1389-1397.
29. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr. 2010;53:323-332.
30. Adams J, Patel N, Mankaryous N, et al. Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents. Ann Pharmacother. 2010;44:157-165.
31. Picchio G, Vingerhoets J, Tambuyzer L, et al. Prevalence of genotypic and phenotypic susceptibility to etravirine in US samples received for routine resistance testing [abstract MOPDB105]. Presented at: 18th International AIDS Conference; July 18-23, 2010; Vienna, Austria.
32. Azijn H, Tirry I, Vingerhoets J, et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wildtype and NNRTI-resistant HIV-1. Antimicrob Agents Chemother. 2010; 54:718-727.
33. Kulkarni R, Babaoglu K, Lansdon E, et al. The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness. J Acquir Immune Defic Syndr. 2012;59:48-55.
34. Xu HT, Asahchop EL, Oliveira M, et al. Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity. J Virol. 2011;85:11300-11308.
35. Hu ZX, Li J, Gallien S, et al. Impact of the interactions of rilpivirine (E138K) and lamivudine/emtricitabine (M184V/I) resistance mutations on viral DNA synthesis and fitness of HIV-1 [abstract 12]. Antivir Ther. 2011;16(suppl 1):A20.
36. Wilkin A, Pozniak AL, Morales-Ramirez J, et al. Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase llb randomized trial. AIDS Res Hum Retroviruses. 2011. Epub ahead of print.